Navigation Links
Encision's Active Electrode Monitoring Technology Recommended at Minimally Invasive Gynecology Congress

BOULDER, Colo., Nov. 17, 2010 /PRNewswire/ -- Active electrode monitoring developed and manufactured by Boulder-based Encision Inc. (Pink Sheets: ECIA), is the only monopolar energy technology proposed as a solution to eliminate visceral burns during Single Port Laparoscopy according to a recent study presentation.  Encision is a medical device company owning patented surgical technology that is emerging as a standard of care in minimally invasive surgery.

The recommendations come as a result of a study reported by Dr. Basim Abu-Rafea at the 39th  American Association of Gynecological Laparoscopists Global Congress of Minimally Invasive Gynecology.  Dr. Abu-Rafea's paper, Single Port Laparoscopy and Monopolar Electrosurgery May Result in Visceral Burns, examined the effects of monopolar electrosurgery on various tissues/organs during simulated single port laparoscopic surgery in vitro and in vivo.

Dr. Abu-Rafea's conclusion was that "Monopolar electrosurgery during endoscopic surgery, compared with other energy sources, is associated with unique inherent risks and complications due to inadvertent direct coupling, capacitive coupling and insulation failure."  Dr. Abu-Rafea continued, "These dangers become particularly important with the emergence of single port laparoscopy which requires close proximity and crossing of multiple intra-abdominal instruments."  

Dr. Abu-Rafea also added, "During single port laparoscopy and use of monopolar energy, the proximity and crossing of instruments generates capacitive and/or direct coupled currents which may cause visceral burns.  Proposed solutions include the use of active electrode monitoring when performing single port laparoscopy to prevent capacitive coupling and direct coupling or consider using other forms of energy such as harmonic or bipolar."  

Jack Serino, Encision's president and CEO, responded in saying, "We are pleased that Encision's active electrode monitoring technology was again recognized as an important consideration to avoid inadvertent patient burns with the growing popularity of single port laparoscopy."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. The Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in our filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.


Marcia McHaffie, Encision Inc., 303-444-2600,

SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
2. New Minimally Invasive Breast Reconstructive Procedure for Breast Cancer Patients - Actively Recruiting Participants for Clinical Study
3. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
4. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
5. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
6. New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
7. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
8. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
9. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
10. Going Beyond Spa Day: Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits
11. Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):